 Heres a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks Biotech stocks that hit 52-week highs on Feb. 20. Akebia Therapeutics Inc NASDAQ: AKBA Aptose Biosciences Inc NASDAQ: APTO Arcturus Therapeutics Ltd NASDAQ: ARCT Arcus Biosciences Inc NYSE: RCUS BELLUS Health Inc NASDAQ: BLU Bio-Rad Laboratories, Inc. Class A Common Stock NYSE: BIO Calithera Biosciences Inc NASDAQ: CALA Cue Biopharma Inc NASDAQ: CUE DexCom, Inc. NASDAQ: DXCM Fate Therapeutics Inc NASDAQ: FATE GENMAB ASS ADR NASDAQ: GMAB Grifols SA - ADR ADR Class B NASDAQ: GRFS Halozyme Therapeutics, Inc. NASDAQ: HALO Intuitive Surgical, Inc. NASDAQ: ISRG Masimo Corporation NASDAQ: MASI announced its fourth-quarter results Medpace Holdings Inc NASDAQ: MEDP Mersana Therapeutics Inc NASDAQ: MRSN Momenta Pharmaceuticals, Inc. NASDAQ: MNTA Relmada Therapeutics Inc NASDAQ: RLMD Repro-Med Systems, Inc. NASDAQ: KRMD Revance Therapeutics Inc NASDAQ: RVNC announced 287.5-million debt offering Revolution Medicines Inc NASDAQ: RVMD went public Feb. 13 Scpharmaceuticals Inc NASDAQ: SCPH Soligenix, Inc. 